BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1470 related articles for article (PubMed ID: 30652428)

  • 1. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
    Bayraktar S; Elsayegh N; Gutierrez Barrera AM; Lin H; Kuerer H; Tasbas T; Muse KI; Ready K; Litton J; Meric-Bernstam F; Hortobagyi GN; Albarracin CT; Arun B
    Cancer; 2012 Mar; 118(6):1515-22. PubMed ID: 22009639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of BRCA1 and BRCA2 Mutations Among High-risk Bahraini Patients with Breast Cancer.
    Bukamal Z; AlRayes A
    Gulf J Oncolog; 2023 May; 1(42):22-25. PubMed ID: 37283256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ductal carcinoma in situ in BRCA mutation carriers.
    Hwang ES; McLennan JL; Moore DH; Crawford BB; Esserman LJ; Ziegler JL
    J Clin Oncol; 2007 Feb; 25(6):642-7. PubMed ID: 17210933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
    Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
    BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.
    Elsayegh N; Kuerer HM; Lin H; Gutierrez Barrera AM; Jackson M; Muse KI; Litton JK; Albarracin C; Afrough A; Hortobagyi GN; Arun BK
    Ann Surg Oncol; 2014 Oct; 21(11):3466-72. PubMed ID: 24796968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
    Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
    BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
    Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
    Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat; ; . PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 74.